- Basic clinical data of 602 patients with diffuse large B-cell lymphoma.
| Factors | AII | HBsAg(+) group | HBsAg(-) group | P-value |
|---|---|---|---|---|
| (n=602) | (n=154) | (n=448) | ||
| Age | 59.72 ±14.14 | 61.57 ± 12.45 | 59.09 ± 14.61 | 0.060 |
| Gender | 0.955 | |||
| Male | 310(51.5%) | 79(51.3%) | 231(51.6%) | |
| Female | 292(48.5%) | 75(48.7%) | 217(48.4%) | |
| Stage | <0.001* | |||
| I–II | 248(41.2%) | 32(20.8%) | 216(48.2%) | |
| III–IV | 354(58.8%) | 122(79.2%) | 232(51.8%) | |
| IPI score | <0.001* | |||
| 0–2 | 389(64.6%) | 59(38.3%) | 330(73.7%) | |
| 3–5 | 213(35.4%) | 95(61.7%) | 118(26.3%) | |
| B symptoms | <0.001* | |||
| Yes | 217(36.1%) | 79(51.3%) | 138(30.8%) | |
| No | 385(64.0%) | 75(48.7%) | 310(69.2%) | |
| Hans classification | 0.635 | |||
| GCB | 256(45.5%) | 68(41.2%) | 188 (42.0%) | |
| Non-GCB | 346(57.5%) | 86(58.8%) | 260 (58.0%) | |
| Extranodal involvement | 0.473 | |||
| Yes | 197(32.7%) | 54(35.1%) | 143 (31.9%) | |
| NO | 405(67.3%) | 100(64.9%) | 305 (68.1%) | |
| Therapy | 0.399 | |||
| CHOP | 74(12.3%) | 22 (14.3%) | 52 (11.6%) | |
| R-CHOP | 336(55.8%) | 89 (57.8%) | 247 (55.1%) | |
| Other | 192(31.9%) | 43 (27.9%) | 149 (33.3%) | |
| Hepatic impairment | 0.001* | |||
| Yes | 102(16.9%) | 39 (25.3%) | 63 (14.1%) | |
| NO | 500(83.1%) | 115 (74.7%) | 385 (85.9%) | |
| Recurrence | ||||
| Yes | 164(27.24%) | 46(29.87%) | 103(23.0%) | 0.035* |
| NO | 438(72.76%) | 108(70.1%) | 345(77.0%) |
IPI: international prognostic index, GCB: germinal center B cell. Hepatic impairment is defined as ALT/AST or blood bilirubin > the upper limit of normal.
↵* P<0.05 was considered statistically significant.